Attack on amyloid-β protein

Eric M. Reiman ()
Additional contact information
Eric M. Reiman: Eric M. Reiman is at the Banner Alzheimer's Institute, Phoenix, Arizona 85006 USA.

Nature, 2016, vol. 537, issue 7618, 36-37

Abstract: An antibody therapy markedly reduces aggregates of amyloid-β, the hallmark protein of Alzheimer's disease, and might slow cognitive decline in patients. Confirmation of a cognitive benefit would be a game-changer. See Article p.50

Date: 2016
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/537036a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:537:y:2016:i:7618:d:10.1038_537036a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/537036a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().